The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
|Videos|November 14, 2017
Dr. Galsky on Resistance to Checkpoint Blockade in Metastatic Bladder Cancer
Author(s)Matthew Galsky, MD
Matthew Galsky, MD, professor of medicine, hematology and medical oncology, Mount Sinai Hospital, discusses resistance to checkpoint blockade in metastatic bladder cancer.
Advertisement
Matthew Galsky, MD, professor of medicine, hematology and medical oncology, Mount Sinai Hospital, discusses resistance to checkpoint blockade in metastatic bladder cancer.
There is a growing understanding about mechanisms of intrinsic and acquired resistance to checkpoint blockade in metastatic bladder cancer.
The main reason that patients don’t respond to checkpoint inhibitors is still not fully understood, says Galsky.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved belzutifan (Welireg) plus lenvatinib (Lenvima) for use in patients with advanced renal cell carcinoma with a clear cell component after PD-1 or PD-L1 inhibition.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
3
FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC
4
FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC
5